Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on June 11, 2013. The filing reports the entry into a Material Definitive Agreement regarding the acquisition of intellectual property rights.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The transaction involves contingent financial obligations rather than immediate cash outflows.
Material Changes and Transaction Details
On June 11, 2013, the Company acquired intellectual property rights from the compounding pharmacy operations of Buderer Drug Company, Inc. pursuant to an Asset Purchase Agreement. Key terms include:
- Acquisition: Rights to proprietary innovations and a right of first refusal on additional Buderer intellectual property.
- Consideration:
- One payment within 30 days of the issuance of the first U.S. patent (if any).
- One payment within 30 days of filing the first Investigational New Drug (IND) application (if any).
- Royalty payments based on net receipts from sales or licensing, after deducting development costs.
- Termination Clause: If the Company does not file an IND within five years, Buderer may terminate the agreement and reclaim the technology.
Guidance, Outlook, and Risks
The Company is obligated to use commercially reasonable efforts to research, develop, and commercialize a product based on the acquired intellectual property. Buderer will cooperate in obtaining patent protection. The primary risk is the failure to file an IND within five years, which would result in the loss of the acquired technology.
Investor Verification Checklist
- Verify the specific scope of the intellectual property acquired from Buderer Drug Company, Inc.
- Monitor the Company's progress toward filing an Investigational New Drug (IND) application to avoid termination of the agreement.
- Review future filings for details on the valuation of the contingent payments and royalty rates.
- Confirm the status of any patent applications arising from this agreement.